GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The Company’s segments include Commercial Operations and Research and Development. The firm is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The firm also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The firm also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
Dame Emma Walmsley est le Chief Executive Officer de GSK plc, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action GSK plc ?
Le prix actuel de GSK plc est de $50.2, il a diminué de 0.41% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de GSK plc ?
GSK plc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de GSK plc ?
La capitalisation boursière actuelle de GSK plc est de $100.1B
Est-ce que GSK plc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 24 analystes ont établi des notations d'analystes pour GSK plc, y compris 6 achat fort, 8 achat, 14 maintien, 3 vente et 6 vente forte
